ISPRI Breakthrough Enhances Biologic Therapeutics Development

02 April 2024 | Tuesday | News

EpiVax Introduces ISPRI, Empowering Researchers with Advanced Computational Tools for Precise Immunogenicity Evaluation in Preclinical Stages
Image Source : Public Domain

Image Source : Public Domain


Developed over many years by EpiVax bioinformaticians, ISPRI provides researchers with a secure interface comprised of integrated computational tools that enable a systematic approach to streamline the assessment and mitigation of immunogenic potential and accelerate overall preclinical development efforts.

The tools, each of which play a critically important role in the assessment process, include: EpiMatrix for T cell epitope mapping, ClustiMer for the identification of epitope-dense regions that could be key to further testing/deimmunization, JanusMatrix for characterizing epitopes (the identification of potentially tolerated or actively tolerogenic epitopes, like Tregitopes), and OptiMatrix for sequence modifications to mitigate immunogenic risks.

Notably, the ISPRI tools can be applied at different stages of development, from early-stage discovery for a high-throughput screening of hits, to comprehensive assessment of a lead candidate in preparation for IND-filing and development of an Integrated Summary of Immunogenicity (ISI).

Further, the toolkit is useful for the screening of all biologic therapeutic modalities, from monoclonal antibodies to bi-specifics, multi-specifics, antibody-drug conjugates, enzyme replacement proteins, CAR-T, gene therapy products, and peptide drugs.

Annie De Groot, MD, CSO, emphasized the significance of ISPRI in advancing biologic therapeutics development, stating that: "ISPRI stands as a pivotal tool in the pursuit of safer, more effective biologic therapeutics, empowering researchers to navigate the complexities of immunogenicity with precision and confidence."

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in